Could GLP-1 Drugs Improve Thinking and Memory in Schizophrenia? | Research

The takeaway

Preclinical evidence suggests GLP-1 receptor agonists may improve cognitive function in schizophrenia, a condition currently lacking any approved treatments for its debilitating cognitive symptoms.

Zero approved treatments
Cognitive impairment in schizophrenia has no approved medication. GLP-1 receptor agonists show preclinical promise for filling this critical gap

What the researchers found

Preclinical evidence supports GLP-1 receptor agonists as potential cognitive enhancers, with activity in brain regions involved in learning and memory, though clinical evidence in schizophrenia is still needed.

Why it matters

Cognitive impairment in schizophrenia has no approved treatment and is the biggest predictor of long-term disability. Repurposing GLP-1 drugs already proven safe for other conditions could fill this critical therapeutic gap.

The numbers in context

~1% worldwide prevalence of schizophrenia; no approved cognitive treatments; GLP-1RAs improve memory, learning, neuroprotection in rodent models

How the study worked

Narrative review of preclinical and early clinical literature on GLP-1RA effects on cognition, with focus on potential applications in schizophrenia.

Who was studied

Review of preclinical GLP-1RA cognitive studies with relevance to schizophrenia

What this study cannot tell us

Review based primarily on preclinical (animal) evidence. Cognitive effects in animal models may not translate to human schizophrenia. Clinical trials specifically testing GLP-1RAs for schizophrenia cognition are limited.

How to read the evidence

Not applicable (narrative review). Based primarily on preclinical evidence with limited clinical data for this specific indication.

When this study was published

Published 2021. Clinical trials investigating GLP-1 drugs for cognition in psychiatric conditions are now underway.

The bigger picture

GLP-1 drugs are increasingly being explored for neuropsychiatric conditions beyond their original metabolic indications. If cognitive benefits are confirmed in schizophrenia trials, it would dramatically expand the clinical reach of these peptide drugs.

Questions still open

Which specific cognitive domains (memory, attention, executive function) are most responsive to GLP-1 agonists?
Would GLP-1 drugs improve cognition in schizophrenia patients already on antipsychotics?
Are the neuroprotective effects of GLP-1 drugs sufficient to address the neurodevelopmental basis of cognitive impairment in schizophrenia?

Common questions

Can diabetes drugs help with schizophrenia?

Possibly. GLP-1 receptor agonists (like semaglutide) work on brain receptors involved in learning and memory. Animal studies show they can improve cognitive function, and researchers are investigating whether these benefits extend to the cognitive problems in schizophrenia.

Why is cognitive impairment in schizophrenia so hard to treat?

Current antipsychotics target dopamine receptors, which helps with hallucinations and delusions but does little for cognitive symptoms. The brain mechanisms underlying cognitive impairment in schizophrenia are complex and likely involve multiple neurotransmitter systems including those targeted by GLP-1.

Read the original research

Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential.

Expert opinion on investigational drugs, 30(8), 877-891

View on PubMed ↗Publisher’s paper ↗

Citation

Flintoff, Jonathan; Kesby, James P; Siskind, Dan; Burne, Thomas Hj. (2021). Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential.. Expert opinion on investigational drugs, 30(8), 877-891. https://doi.org/10.1080/13543784.2021.1951702